The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
Berson, S. A., Yalow, R. S., Bauman, A., Rothschild, M. A., & Newerly, K. (1956) · Journal of Clinical Investigation · doi:10.1172/jci103262 · Cited by 836
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Mire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
Self-citationImmunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Bioequivalence and the immunogenicity of biopharmaceuticals
Schellekens, H. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd818 · Cited by 534
Factors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Allergic Reactions to Drugs and Biologic Agents
deShazo, R. D. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550220101014 · Cited by 227
ANTI-IDIOTYPIC AND NON-ANTI-INDIOTYPIC ANTIBODIES TO OKT3 ARISING DESPITE INTENSE IMMUNOSUPPRESSION
Jaffers, G. J., Fuller, T. C., Cosimi, A. B., Russell, P. S., Winn, H. J., & Colvin, R. B. (1986) · Transplantation · doi:10.1097/00007890-198605000-00004 · Cited by 185
Scientific and regulatory considerations on the immunogenicity of biologics
Shankar, G., Shores, E., Wagner, C., & Mire-Sluis, A. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2006.04.001 · Cited by 175
Self-citation
Cited by
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Roadmap for implementation of quality by design (QbD) for biotechnology products
Rathore, A. S. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.06.006 · Cited by 411
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Shankar, G., Arkin, S., Cocea, L., Devanarayan, V., Kirshner, S., Kromminga, A., Quarmby, V., Richards, S., Schneider, C. K., Subramanyam, M., et al. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9599-2 · Cited by 353
Self-citation
Metadata
- Authors
- Shankar, G., Pendley, C., & Stein, K. E.
- Venue
- Nature Biotechnology
- Published
- 2007-05
- Volume
- 25
- Issue
- 5
- Pages
- 555-561
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2012027479
- Cited by
- 260
- References
- 23
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. https://app.cochat.ai/papers/10.1038/nbt1303
- The paper
- Shankar, G., Pendley, C., & Stein, K. E. (2007). A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nature Biotechnology. https://doi.org/10.1038/nbt1303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
